RWE 101 – Is ‘Retrospective Data’ the Same as ‘Secondary Use of Existing Data’?
Retrospective data generally refers to data that has already been collected for another purpose and is being used retrospectively to answer a new research question. This data can come from various sources, such as electronic health records, claims databases, or patient registries, and is often used to generate RWE.
On the other hand, secondary use of existing data refers to the practice of using existing data for a purpose other than the one for which it was originally collected. This can include using data from clinical trials for post-market surveillance or using data from a patient registry for comparative effectiveness research.
While retrospective data can be one type of existing data that is used for secondary purposes, not all secondary uses of data involve retrospective data. For example, prospective data collected for one purpose, such as routine clinical care, can be used for secondary purposes, such as generating RWE.
In summary, retrospective data and secondary use of existing data are related but not interchangeable terms in the context of RWE. Retrospective data is a type of existing data that can be used for secondary purposes, but not all secondary uses of data involve retrospective data.
Share this story...
Real World Evidence (RWE) 101 – Patient Retention
RWE 101 - Patient Retention Long-term Real-World Evidence (RWE) studies face significant challenges when it comes to patient retention, for several reasons:[1] Time Commitment: Participants in RWE studies are [...]
Real World Evidence (RWE) 101 – Patient Recruitment
RWE 101 - Patient Recruitment Real-world evidence (RWE) is health care information derived from real-world data (RWD). It can be generated through various study designs or analyses, including pragmatic [...]
Real World Evidence (RWE) 101 – HARPER
RWE 101 - HARPER Regulatory agencies, health technology assessors, and payers are increasingly interested in studies that make use of real-world data to inform regulatory and other policy or [...]
Real World Evidence (RWE) 101 – STaRT-RWE
RWE 101 - STaRT-RWE START-RWE (Structured Template for Planning and Reporting on the Implementation of Real World Evidence Studies) was developed to address the need for improved transparency and [...]
Real World Evidence (RWE) 101 – Protocol Design and ISPE GPP
RWE 101 - Protocol Design and ISPE GPP The International Society for Pharmacoepidemiology (ISPE) Guidelines for Good Pharmacoepidemiology Practices (GPP) are a set of best practices for the conduct [...]
Real World Evidence (RWE) 101 – Protocol Design and Scientific Best Practices
RWE 101 - Protocol Design and Scientific Best Practices Designing a robust Real-World Evidence (RWE) study is crucial for generating reliable and valid insights that are acceptable to regulators. [...]
